Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab

Inclusion Criteria: * Female patients with confirmed HER-2 positive , non-operable locally advanced or metastatic breast cancer * All patients must have received at least 1 but no more than 2 prior anti HER2 based regimens including at least 1 regimen containing Trastuzumab. * All patients must have at least one measurable lesion as defined by RECIST criteria. * All patients must have documented progressive disease following the last line of therapy before entering the study * ECOG Performance status ≤ 1 Exclusion Criteria: * Patients with known CNS metastasis which are: symptomatic or require treatment for symptom control and/or growing * Prior treatment with any HSP90 or HDAC inhibitor * Impaired cardiac function * Acute or chronic liver or renal disease * Patients who are currently receiving treatment with any medication which has a relative risk of prolonging the QTc interval or inducing Torsades de Pointes and cannot be switched or discontinued to an alternative drug prior to commencing AUY922 * Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention * Patients who do not have either an archival tumor sample available or are unwilling to have a fresh tumor sample collected at baseline. Other protocol-defined inclusion/exclusion criteria may apply